Literature DB >> 21365326

The TP53 gene polymorphisms and survival of sporadic breast cancer patients.

V Bišof1, M Peričić Salihović, N Smolej Narančić, T Skarić-Jurić, J Jakić-Razumović, B Janićijević, P Rudan.   

Abstract

The TP53 gene polymorphisms, Arg72Pro and PIN3 (+16 bp), can have prognostic and predictive value in different cancers including breast cancer. The aim of the present study is to investigate a potential association between different genotypes of these polymorphisms and clinicopathological variables with survival of breast cancer patients in Croatian population. Ninety-four women with sporadic breast cancer were retrospectively analyzed. Median follow-up period was 67.9 months. The effects of basic clinical and histopathological characteristics of tumor on survival were tested by Cox's proportional hazards regression analysis. The TNM stage was associated with overall survival by Kaplan-Meier analysis, univariate, and multivariate Cox's proportional hazards regression analysis, while grade was associated with survival by Kaplan-Meier analysis and univariate Cox's proportional hazards regression analysis. Different genotypes of the Arg72Pro and PIN3 (+16 bp) polymorphisms had no significant impact on survival in breast cancer patients. However, in subgroup of patients treated with chemotherapy without anthracycline, the A2A2 genotype of the PIN3 (+16 bp) polymorphism was associated with poorer overall survival than other genotypes by Kaplan-Meier analysis (P = 0.048). The TP53 polymorphisms, Arg72Pro and PIN3 (+16 bp), had no impact on survival in unselected sporadic breast cancer patients in Croatian population. However, the results support the role of the A2A2 genotype of the PIN3 (+16 bp) polymorphism as a marker for identification of patients that may benefit from anthracycline-containing chemotherapy.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21365326     DOI: 10.1007/s12032-011-9875-2

Source DB:  PubMed          Journal:  Med Oncol        ISSN: 1357-0560            Impact factor:   3.064


  25 in total

1.  p53 Codon 72 polymorphism predicts the pathologic response to neoadjuvant chemotherapy in patients with breast cancer.

Authors:  Ye Xu; Lihua Yao; Tao Ouyang; Jinfeng Li; Tianfeng Wang; Zhaoqing Fan; Benyao Lin; Youyong Lu; Yuntao Xie
Journal:  Clin Cancer Res       Date:  2005-10-15       Impact factor: 12.531

2.  p53 polymorphic variants at codon 72 and the outcome of therapy in randomized breast cancer patients.

Authors:  Pia Wegman; Olle Stal; Marie Stenmark Askmalm; Bo Nordenskjöld; Lars-Erik Rutqvist; Sten Wingren
Journal:  Pharmacogenet Genomics       Date:  2006-05       Impact factor: 2.089

3.  Two polymorphic variants of wild-type p53 differ biochemically and biologically.

Authors:  M Thomas; A Kalita; S Labrecque; D Pim; L Banks; G Matlashewski
Journal:  Mol Cell Biol       Date:  1999-02       Impact factor: 4.272

4.  p53 Genotypes and Haplotypes Associated With Lung Cancer Susceptibility and Ethnicity.

Authors:  Xifeng Wu; Hua Zhao; Christopher I Amos; Sanjay Shete; Nimisha Makan; Waun K Hong; Fred F Kadlubar; Margaret R Spitz
Journal:  J Natl Cancer Inst       Date:  2002-05-01       Impact factor: 13.506

5.  Associations between common polymorphisms in TP53 and p21WAF1/Cip1 and phenotypic features of breast cancer.

Authors:  Brenda L Powell; Iris L van Staveren; Paul Roosken; Fabienne Grieu; Els M J J Berns; Barry Iacopetta
Journal:  Carcinogenesis       Date:  2002-02       Impact factor: 4.944

6.  p53 polymorphism influences response in cancer chemotherapy via modulation of p73-dependent apoptosis.

Authors:  Daniele Bergamaschi; Milena Gasco; Louise Hiller; Alexandra Sullivan; Nelofer Syed; Giuseppe Trigiante; Isik Yulug; Marco Merlano; Gianmauro Numico; Alberto Comino; Marlene Attard; Olivier Reelfs; Barry Gusterson; Alexandra K Bell; Victoria Heath; Mahvash Tavassoli; Paul J Farrell; Paul Smith; Xin Lu; Tim Crook
Journal:  Cancer Cell       Date:  2003-04       Impact factor: 31.743

7.  p53 polymorphic variants at codon 72 exert different effects on cell cycle progression.

Authors:  David Pim; Lawrence Banks
Journal:  Int J Cancer       Date:  2004-01-10       Impact factor: 7.396

8.  The codon 72 polymorphic variants of p53 have markedly different apoptotic potential.

Authors:  Patrick Dumont; J I-Ju Leu; Anthony C Della Pietra; Donna L George; Maureen Murphy
Journal:  Nat Genet       Date:  2003-02-03       Impact factor: 38.330

9.  The p53 codon 72 proline allele is endowed with enhanced cell-death inducing potential in cancer cells exposed to hypoxia.

Authors:  P Sansone; G Storci; S Pandolfi; L Montanaro; P Chieco; M Bonafé
Journal:  Br J Cancer       Date:  2007-04-03       Impact factor: 7.640

10.  Association of TP53 codon 72 polymorphism and the outcome of adjuvant therapy in breast cancer patients.

Authors:  Tatsuya Toyama; Zhenhuan Zhang; Mariko Nishio; Maho Hamaguchi; Naoto Kondo; Hirotaka Iwase; Hiroji Iwata; Satoru Takahashi; Hiroko Yamashita; Yoshitaka Fujii
Journal:  Breast Cancer Res       Date:  2007       Impact factor: 6.466

View more
  3 in total

Review 1.  Deregulation of the EGFR/PI3K/PTEN/Akt/mTORC1 pathway in breast cancer: possibilities for therapeutic intervention.

Authors:  Nicole M Davis; Melissa Sokolosky; Kristin Stadelman; Steve L Abrams; Massimo Libra; Saverio Candido; Ferdinando Nicoletti; Jerry Polesel; Roberta Maestro; Antonino D'Assoro; Lyudmyla Drobot; Dariusz Rakus; Agnieszka Gizak; Piotr Laidler; Joanna Dulińska-Litewka; Joerg Basecke; Sanja Mijatovic; Danijela Maksimovic-Ivanic; Giuseppe Montalto; Melchiorre Cervello; Timothy L Fitzgerald; Zoya Demidenko; Alberto M Martelli; Lucio Cocco; Linda S Steelman; James A McCubrey
Journal:  Oncotarget       Date:  2014-07-15

Review 2.  Genetics of breast cancer in African populations: a literature review.

Authors:  A Abbad; H Baba; H Dehbi; M Elmessaoudi-Idrissi; Z Elyazghi; O Abidi; F Radouani
Journal:  Glob Health Epidemiol Genom       Date:  2018-05-11

3.  Genotype and Haplotype Analyses of TP53 Gene in Breast Cancer Patients: Association with Risk and Clinical Outcomes.

Authors:  Veronika Vymetalkova; Pavel Soucek; Tereza Kunicka; Katerina Jiraskova; Veronika Brynychova; Barbara Pardini; Vendula Novosadova; Zdena Polivkova; Katerina Kubackova; Renata Kozevnikovova; Miloslav Ambrus; Ludmila Vodickova; Alessio Naccarati; Pavel Vodicka
Journal:  PLoS One       Date:  2015-07-30       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.